Radioimmunotherapy and stem-cell transplantation in the treatment of aggressive B-cell lymphoma

References

• Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Philip T, Armitage J O, Spitzer G, Chauvin F, Jagannath S, Cahn J Y, et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Vose J M, Zhang M J, Rowlings P A, Lazarus H M, Bolwell B J, Freytes C O, et al. Autologous transplantation for diffuse aggressive non-Hodgkin's lymphoma in patients never achieving remission: a report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 2001; 19: 406–413
   PubMed Web of Science ®Google Scholar
• Shipp M A, Abeloff M D, Antman K H, Carroll G, Hagenbeek A, Loeffler M, et al. International Consensus Conference on High-Dose Therapy with Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429
   PubMed Web of Science ®Google Scholar
• Hahn T, Wolff S N, Czuczman M, Fisher R I, Lazarus H M, Vose J, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review. Biol Blood Marrow Transplant 2001; 7: 308–331
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Brière J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Hess G, Flohr T, Derigs H G. Rituximab as in vivo purging agent in autologous stem cell transplantation for relapsed B-NHL. Ann Hematol 2002; 81(Suppl 2)S54–S55
   PubMed Web of Science ®Google Scholar
• Flinn I W, O'Donnell P V, Goodrich A, Vogelsang G, Abrams R, Noga S, et al. Immunotherapy with rituximab during peripheral blood stem cell transplantation for non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2000; 6: 628–632
   PubMed Web of Science ®Google Scholar
• Khouri I, Saliba R M, Hosing C, Okoroji G J, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 2240–2247
   PubMed Web of Science ®Google Scholar
• Shimoni A, Hardan I, Avigdor A, Yeshurun M, Raanani P, Ben-Bassat I, et al. Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high-risk aggressive non-Hodgkin's lymphoma. Br J Haematol 2003; 122: 457–464
   PubMed Web of Science ®Google Scholar
• Horwitz S M, Negrin R S, Blume K G, Breslin S, Stuart M J, Stockerl-Goldstein K E, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004; 103: 777–783
   PubMed Web of Science ®Google Scholar
• Brown J R, Yeckes H, Friedberg J W, Neuberg D, Kim H, Nadler L M, et al. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 2208–2214
   PubMed Web of Science ®Google Scholar
• Sebban C, Mounier N, Brousse N, Belanger C, Brice P, Haioun C, et al. Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 2006; 108: 2540–2544
   PubMed Web of Science ®Google Scholar
• Cheson B D. Radioimmunotherapy of non-Hodgkin lymphomas. Blood 2003; 101: 391–398
   PubMed Web of Science ®Google Scholar
• Witzig T E. Radioimmunotherapy for B-cell non-Hodgkin lymphoma. Best Pract Res Clin Haematol 2006; 19: 655–668
   PubMed Web of Science ®Google Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani P L, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54–58
   PubMed Web of Science ®Google Scholar
• Maloney D G, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29: 2–9
   PubMed Web of Science ®Google Scholar
• Knox S J, Levy R, Miller R A, Uhland W, Schiele J, Ruehl W, et al. Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res 1990; 50: 4935–4940
   PubMed Web of Science ®Google Scholar
• Skvortsova I, Skvortsov S, Popper B A, Haidenberger A, Saurer M, Gunkel A R, et al. Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and -independent mechanisms. J Radiat Res 2006; 47: 183–196
   PubMed Web of Science ®Google Scholar
• Vose J M, Wahl R L, Saleh M, Rohatiner A Z, Knox S J, Radford J A, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2000; 18: 1316–1323
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Zelenetz A D, Press O W, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001; 19: 3918–3928
   PubMed Web of Science ®Google Scholar
• Kaminski M S, Tuck M, Estes J, Kolstad A, Ross C W, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005; 352: 441–449
   PubMed Web of Science ®Google Scholar
• Fisher R I, Kaminski M S, Wahl R L, Knox S J, Zelenetz A D, Vose J M, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005; 23: 7565–7573
   PubMed Web of Science ®Google Scholar
• Witzig T E, Flinn I W, Gordon L I, Emmanouilides C, Czuczman M S, Saleh M N, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 3262–3269
   PubMed Web of Science ®Google Scholar
• Wiseman G A, Gordon L I, Multani P S, Witzig T E, Spies S, Bartlett N L, et al. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial. Blood 2002; 99: 4336–4342
   PubMed Web of Science ®Google Scholar
• Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002; 20: 2453–2463
   PubMed Web of Science ®Google Scholar
• Witzig T E, Molina A, Gordon L I, Emmanouilides C, Schilder R J, Flinn I W, et al. Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan. Cancer 2007; 109: 1804–1810
   PubMed Web of Science ®Google Scholar
• Liu S Y, Eary J F, Petersdorf S H, Martin P J, Maloney D G, Appelbaum F R, et al. Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue. J Clin Oncol 1998; 16: 3270–3278
   PubMed Web of Science ®Google Scholar
• Gopal A K, Rajendran J G, Goley T A, Pagel J M, Fisher D R, Petersdorf S, et al. Phase II study of myeloablative I-131 anti CD20 (tositumomab) radioimmunotherapy and autologous hematopoietic stem cell transplantation (ASCT) for adults > 60 years of age with high-risk relapsed or refractory B-cell lymphoma. J Clin Oncol 2007; 25: 1396–1402
   PubMed Web of Science ®Google Scholar
• Flinn I W, Kahl B S, Frey E C, Bianco J A, Hammes R J, Webb J, et al. Dose finding trial of Yttrium 90 ibritumomab tiuxetan (90YIT0 with autologous stem cell transplantation in patients with relapse or refractory B-cell non-Hodgkin's lymphoma (NHL). J Clin Oncol 2006; 24: 7535, (abstr)
   Google Scholar
• Vanazzi A, Ferrucci P F, Grana C, Cremonesi M, Clerici M, Radice D, et al. High dose 90Yttrium ibritumomab tiuxetan (Zevalin) treatment with PBSC support in refractory-resistant NHL patients: a phase I/II study. Blood 2006; 108: 2720, (abstr)
   PubMed Web of Science ®Google Scholar
• Devizzi L, Seregni E, Guidetti A, Fomi C, Coliva A, Magni M, et al. High dose myeloablative Zevalin radioimmunotherapy with tandem stem-cell autografting has promising activity, minimal toxicity and full feasibility in an outpatient setting. Blood 2006; 108: 3047, (abstr)
   Google Scholar
• Press O W, Eary J F, Gooley T, Gopal A K, Liu S, Rajendran J G, et al. A phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood 2000; 96: 2934–2942
   PubMed Web of Science ®Google Scholar
• Nademanee A, Krishnan A Y, Tsai N, Palmer J, Molina A, Fung H, et al. Yttrium 90 ibritumomab tiuxetan (Zevalin) in combination with high-dose therapy (HDT) followed by autologous stem cell transplant (ASCT) may improve survival in patients with poor-risk follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL): results of a retrospective comparative analysis. Blood 2006; 108: 327, (abstr)
   Google Scholar
• Nademanee A, Forman S, Molina A, Fung H, Smith D, Dagis A, et al. A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma. Blood 2005; 106: 2896–2902
   PubMed Web of Science ®Google Scholar
• Winter J N, Inwards D, Spies S, Wiseman G, Patton D, Erwin W, et al. 90Y ibritumomab tiuxetan (Zevalin) doses calculated to deliver up to 1500 cGy to critical organs may be safely combined with high-dose BEAM and autotransplant in NHL. Blood 2006; 108: 330, (abstr)
   Google Scholar
• Vose J M, Bierman P J, Enke C, Hankins J, Bociek G, Lynch J C, et al. Phase I trial of iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 461–467
   PubMed Web of Science ®Google Scholar
• Krishnan A Y, Nademanee A, Raubitschek A, Fung H, Molina A, Yamauchi D, et al. A comparison of Beam and Yttrium 90 ibritumomab tiuxetan (Zevalin) in addition to Beam (Z-BEAM) in older patients undergoing autologous stem cell transplant (ASCT) for B-cell lymphomas: impact of radioimmunotherapy on transplant outcomes. Blood 2006; 108: 3043, (abstr)
   Google Scholar
• Khouri I F, Saliba R M, Hosing C, Valverde R, Erwin W D, Fayad L, et al. Efficacy and safety of yttrium 90 (90Y) ibritumomab tiuxetan in autologous and nonmyeloablative stem cell transplantation (NST) for relapsed non-Hodgkin's lymphoma (NHL). Blood 2006; 108(Suppl 1), abstract 315
   Google Scholar
• Shimoni A, Zwas S T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, et al. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma. Exp Hematol 2007; 35: 534–540
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J F, Appelbaum F R, Martin P J, Badger C C, Nelp W B, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993; 329: 1219–1224
   PubMed Web of Science ®Google Scholar
• Press O W, Eary J F, Appelbaum F R, Martin P J, Nelp W B, Glenn S, et al. Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346: 336–340
   PubMed Web of Science ®Google Scholar
• Vanazzi A, Ferrucci P F, Ferrari M, Calabrese L, Cremonesi M, Bartolomei M, et al. High dose Zevalin (90Yttrium ibritumomab tiuxetan) treatment with PBSC support in refractory-resistant NHL patients: preliminary results of a phase I/II study. Blood 2005; 106: 488, (abstr)
   Google Scholar
• Gopal A K, Gooley T A, Maloney D G, Petersdorf S H, Eary J F, Rajendran J G, et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 2003; 102: 2351–2357
   PubMed Web of Science ®Google Scholar
• Winter J N. Combining yttrium 90-labeled ibritumomab tiuxetan with high-dose chemotherapy and stem cell support in patients with relapsed non-Hodgkin's lymphoma. Clin Lymphoma 2004; 5(Suppl 1)S22–S26
   PubMedGoogle Scholar
• Butcher B W, Collins R H, Jr. The graft-versus-lymphoma effect: clinical review and future opportunities. Bone Marrow Transplant 2005; 36: 1–17
   PubMed Web of Science ®Google Scholar
• Robinson S P, Goldstone A H, Mackinnon S, Carella A, Russell N, de Elvira C R, et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002; 100: 4310–4316
   PubMed Web of Science ®Google Scholar
• van Besien K, Sobocinski K A, Rowlings P A, Murphy S C, Armitage J O, Bishop M R, et al. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma. Blood 1998; 91: 1178–1184
   PubMed Web of Science ®Google Scholar
• Jones R J, Ambinder R F, Piantadosi S, Santos G W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653
   PubMed Web of Science ®Google Scholar
• Champlin R, Khouri I, Shimoni A, Gajewski J, Kornblau S, Molldrem J, et al. Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy. Br J Haematol 2000; 111: 18–29
   PubMed Web of Science ®Google Scholar
• Nagler A, Slavin S, Varadi G, Naparstek E, Samuel S, Or R. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021–1028
   PubMed Web of Science ®Google Scholar
• Khouri I F, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824
   PubMed Web of Science ®Google Scholar
• Escalon M P, Champlin R E, Saliba R M, Acholonu S A, Hosing C, Fayad L, et al. Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation. J Clin Oncol 2004; 22: 2419–2423
   PubMed Web of Science ®Google Scholar
• Baron F, Maris M B, Sandmaier B M, Storer B E, Sorror M, Diaconescu R, et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 2005; 23: 1993–2003
   PubMed Web of Science ®Google Scholar
• Dean R M, Fowler D H, Wilson W H, Odom J, Steinberg S M, Chow C, et al. Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 593–599
   PubMed Web of Science ®Google Scholar
• Shimoni A, Zwas T, Oksman Y, Hardan I, Shem-Tov N, Yerushalmi R, et al. Ibritumomab tiuxetan (Zevalin®) combined with reduced-intensity conditioning and allogeneic stem cell transplantation in patients with chemo-refractory non-Hodgkin lymphoma. Bone Marrow Transplant 2007; 39(Suppl 1)511, (abstr)
   PubMed Web of Science ®Google Scholar
• Gopal A K, Rajendran J G, Pagel J M, Guthrie K A, Maloney D G, Appelbaum F R, et al. A phase ii trial of 90Y-ibritumomab tiuxetan-based reduced intensity allogeneic peripheral blood stem cell (PBSC) transplantation for relapsed CD20+ B-cell non-Hodgkins lymphoma (NHL). Blood 2006; 108(Suppl 1), abstr 316
   Google Scholar
• Fietz T, Uharek L, Gentilini C, Muessig A, Rieger K, Marinets O, et al. Allogeneic hematopoietic cell transplantation following conditioning with 90Y-ibritumomab-tiuxetan. Leuk Lymphoma 2006; 47: 59–63
   PubMed Web of Science ®Google Scholar